ORION BIOTECHNOLOGY
ORION BIOTECHNOLOGY PRESENTING NEW DATA AT THE GPCR DRUG DISCOVERY SUMMIT
22 mars 2022 09h07 HE | Orion Biotechnology Canada Ltd.
Ottawa, Ontario, Canada, March 22, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs), today...
ORION ANNOUNCES THE
ORION ANNOUNCES THE RAPID LEAD OPTIMIZATION OF OB-004 - A CCR2 ANTAGONIST
30 nov. 2021 10h07 HE | Orion Biotechnology Canada Ltd.
Ottawa, Ontario, Canada, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology, a clinical stage company unlocking the therapeutic potential of  G Protein-Coupled Receptors (GPCRs) with a novel drug...
ORION BIOTECHNOLOGY
ORION BIOTECHNOLOGY RECEIVES FUNDING TO ADVANCE ITS LEAD GPCR-TARGETED THERAPEUTIC
04 nov. 2021 11h03 HE | Orion Biotechnology Canada Ltd.
Ottawa, Canada, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel...
ORION BIOTECHNOLOGY ADDS INDUSTRY LEADER TO BOARD OF DIRECTORS
31 août 2021 10h03 HE | Orion Biotechnology Canada Ltd.
Ottawa, Canada, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology, a clinical stage company that is developing novel G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of...
ORION BIOTECHNOLOGY
ORION BIOTECHNOLOGY SECURES $11.5M SERIES A FINANCING
17 juin 2021 11h03 HE | Orion Biotechnology Canada Ltd.
ottawa, canada, June 17, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical-stage biotechnology company, today announced that it has raised $11.5M USD in a Series A financing.  ...
ORION BIOTECHNOLOGY
ORION BIOTECHNOLOGY WELCOMES NEW MEMBERS OF SCIENTIFIC ADVISORY BOARD
13 avr. 2021 10h05 HE | Orion Biotechnology Canada Ltd.
Ottawa, Canada, April 13, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage biotechnology company focused on precision engineering small protein therapeutics, today...
PHASE 1 TEST RESULTS
PHASE 1 TEST RESULTS FOR A NOVEL HIV PREVENTION GEL PRESENTED AT THE HIVR4P MEETING
28 janv. 2021 10h48 HE | Orion Biotechnology Canada Ltd.
Ottawa, Canada, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today...
ORION BIOTECHNOLOGY
ORION BIOTECHNOLOGY PROJECT AWARDED GRANT TO ADVANCE DRUG DISCOVERY
14 janv. 2021 11h16 HE | Orion Biotechnology Canada Ltd.
Genève SWITZERLAND, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Holding SA., a biotechnology company focused on precision engineering small protein therapeutics, today announced that...
Orion Biotechnology
Orion Biotechnology Successfully Completes Phase 1 Clinical Trial of a First-in-Class Precision Engineered Ligand Analog for HIV Prevention
15 oct. 2020 10h07 HE | Orion Biotechnology Canada Ltd.
OTTAWA, Canada, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering GPCR-targeted therapeutics, today...
Orion Biotechnology
Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19
30 juil. 2020 10h51 HE | Orion Biotechnology Canada Ltd.
Ottawa, Canada, July 30, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today...